HOME ·

02696.HK

HENLIUS (02696.HK): Added as Hang Seng Composite Index Constituent, Effective 7 September
Tags：
HENLIUS02696.HKHang Seng Composite Index
2026-08-21
HENLIUS (02696.HK): enters global strategic partnership with Sandoz covering up to 10 biosimilar products, with upfront and milestone payments totaling up to USD 314 million
Tags：
HENLIUS02696.HKstrategic cooperation
2026-08-17
Henlius (02696.HK): NMPA Approves Clinical Trial Application for HLX43 Combined with Bevacizumab in Solid Tumors
Tags：
HENLIUS02696.HKClinical Trial
2026-07-31
Henlius (02696.HK): First Patient Dosed in Phase 1 Trial of Trispecific Antibody HLX3902 Targeting STEAP1×CD3×CD28
Tags：
HENLIUS02696.HKClinical Trial
2026-07-30
HENLIUS (02696.HK): Biosimilar HLX18 to Nivolumab Doses First Patient in China for Global Multi-centre Phase I Trial
Tags：
HENLIUS02696.HKClinical Trial
2026-07-16
HENLIUS (02696.HK): NMPA Approves Phase I Trial for HLX37 (PD-L1/VEGF Bispecific) Plus Chemotherapy or HLX43 (PD-L1 ADC) in Solid Tumours
Tags：
HENLIUS02696.HKClinical Trial
2026-07-10
HENLIUS(02696.HK): First Patient Dosed in Phase I Clinical Trial of HLX05-N, a Cetuximab Biosimilar, for Metastatic Colorectal Cancer
Tags：
HENLIUS02696.HKClinical Trial
2026-07-08
HENLIUS(02696.HK): Bispecific EGFR/c-MET ADC HLX48 Doses First Patient
Tags：
HENLIUS02696.HKClinical Trial
2026-06-30
Henlius (02696.HK) Serplulimab Approved by EU Commission for First-Line sqNSCLC
Tags：
HENLIUS02696.HKInnovative Drugs
2026-06-25
Henlius(02696.HK): HLX3902 Injection (STEAP1xCD3xCD28 Trispecific Antibody) Gets NMPA Approval for Phase I Clinical Trial in Metastatic Castration-Resistant Prostate Cancer
Tags：
HENLIUS02696.HKInvestigational New Drug application
2026-06-17
Henlius(02696.HK): Hanbeiyou (Pertuzumab Injection) Passes GMP Compliance Inspection, Songjiang Base Eligible for Commercial Production
Tags：
HENLIUS02696.HKGMP compliance inspection
2026-06-17
Henlius(02696.HK):Phase 2 Clinical Trial of HLX43 Combined with Serplulimab for Neoadjuvant Treatment of NSCLC Approved in Australia
Tags：
HENLIUS02696.HKHLX43Clinical Trial
2026-06-16
HENLIUS(02696.HK): HLX04-O Meets Primary Endpoint in Global Multicenter Phase 3 Trial for Wet Age-Related Macular Degeneration
Tags：
HENLIUS02696.HKClinical Trial
2026-06-16
HENLIUS(02696.HK): Hanbeiyou (Pertuzumab Injection) Approved by NMPA for HER2-positive Breast Cancer Treatment
Tags：
HENLIUS02696.HKNew Drug Marketing Application
2026-05-29
Henlius (02696.HK): HLX316 (B7-H3-Targeting Sialidase Fc Fusion Protein) Completes First Patient Dosing in Phase I Trial
Tags：
HENLIUS02696.HKfirst-in-human
2026-05-22
Henlius (02696.HK): HLX48 (EGFR/c-MET Dual-target ADC) Secures Australian Approval for Phase I Clinical Trial
Tags：
HENLIUS02696.HKPhase I clinical trial
2026-05-13
Henlius (02696.HK): HLX97 (KAT6A/B Inhibitor) Completes First Patient Dosing in Phase I Clinical Trial for Advanced Solid Tumors
Tags：
HENLIUS02696.HKPhase I clinical trial
2026-05-13
Henlius (02696.HK): Self-Developed KAT6A/B Inhibitor HLX97 Approved for Clinical Trial
Tags：
HENLIUS02696.HKnew drug launch
2026-03-05
HENLIUS(02696.HK): Enters into License Agreement with Eisai, Authorizing Commercialization of Hansoh® for Oncology Indications in Japan
Tags：
HENLIUS02696.HK
2026-02-05
HENLIUS(02696.HK): Completes H-Share Full Circulation, 182.65 Million Unlisted Shares Converted to H-Shares to List Tomorrow
Tags：
HENLIUS02696.HK
2026-02-04